 |
 Video: What is a Stock Split?
|
|
|
| Sorrento Therapeutics is a clinical stage and commercial biopharmaceutical company that delivers therapies to address unmet medical needs. Co. has programs assessing the use of its technologies and products in autoimmune, inflammatory, viral and neurodegenerative diseases. Co.'s segments are: Sorrento Therapeutics, which includes Sofusa®, a drug delivery technology that delivers biologics into the lymphatic system, and resiniferatoxin, a non-opioid-based neurotoxin in clinical trials for late stage cancer pain and moderate to severe osteoarthritis of the knee pain; and Scilex, which includes ZTlido, a lidocaine topical system for the relief of pain associated with post-herpetic neuralgia. According to our SRNE stock split history records, SRNE has had 0 splits. | |
|
SRNE (SRNE) has 0 splits in our SRNE stock split history database.
Looking at the SRNE stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SRNE shares, starting with a $10,000 purchase of SRNE, presented on a split-history-adjusted basis factoring in the complete SRNE stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/29/2014 |
|
| End date: |
02/22/2023 |
|
| Start price/share: |
$9.40 |
|
| End price/share: |
$0.31 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-96.70% |
|
| Average Annual Total Return: |
-32.07% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$329.61 |
|
| Years: |
8.82 |
|
|
|
|
|
